Div­ing deep in­to AMD, Yale re­searchers pin­point cell types drug de­vel­op­ers should pay spe­cial at­ten­tion to

The wild suc­cess­es of drugs like Eylea and Lu­cen­tis some­times over­shad­ow the fact that there still isn’t a cure for age-re­lat­ed mac­u­lar de­gen­er­a­tion, the lead­ing cause of blind­ness among the el­der­ly, es­pe­cial­ly the ear­li­er-stage dis­ease known as dry AMD. While around three dozen genes tied to the dis­ease have been iden­ti­fied — giv­ing rise to ex­per­i­men­tal gene ther­a­pies — some sci­en­tists be­lieve a clos­er look is need­ed to fig­ure out where ex­act­ly these ge­net­ic al­ter­ations are tak­ing place.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER